1 Differential clinical characteristics across traditional Chinese medicine (TCM)

2 syndromes in patients with sickle cell disease

3

Ying Wang^{1,2*}, David D Wang³, Andrew Q Pucka¹, Andrew RW O'Brien^{2,4}, Steven E Harte⁵ and Richard E Harris^{5,6}

- ⁶ ¹Department of Anesthesia, Stark Neurosciences Research Institute, Indiana University School
- 7 of Medicine, Indianapolis, IN, USA
- ²Division of Hematology/Oncology, Department of Medicine, Indiana University School of
 Medicine, Indianapolis, IN, USA
- ³Center for Integrative Health, The Ohio State University, Columbus, OH, USA
- 11 ⁴Indiana University Simon Cancer Center, Indianapolis, IN, USA
- ⁵Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of
 Michigan Medical School, Ann Arbor, MI, USA
- ⁶Susan Samueli Integrative Health Institute, and Department of Anesthesiology and
- 15 Perioperative Care, School of Medicine, University of California at Irvine, Irvine, CA, USA

16 * Correspondence:

- 17 Corresponding Author
- 18 ywa12@iu.edu

19

- 20 Key words: Sickle cell disease, Pain, Traditional Chinese Medicine, Syndrome differentiation,
- 21 Acupuncture, Patient-reported outcomes, Quantitative sensory testing, Morphine milligram
- 22 equivalents

23 Abstract

- 24 Background: Pain is a common, debilitating, and poorly understood complication of sickle cell
- disease (SCD). The need for clinical pain management of SCD is largely unmet and relies on
- 26 opioids as the main therapeutic option, which leads to a decreased quality of life (QoL).
- 27 According to the literature, acupuncture has shown certain therapeutic effects for pain
- 28 management in SCD. However, these clinical studies lack the guidance of Traditional Chinese
- 29 Medicine (TCM) Syndrome Differentiation principles for treatment.
- 30 Aim: To characterize differences in clinical presentation amongst TCM-diagnosed syndromes in
- 31 SCD patients.
- 32 Method: 52 patients with SCD and 28 age- and sex-matched healthy controls (HCs) were
- 33 enrolled in an ongoing trial of acupuncture. Each participant completed a series of
- 34 questionnaires on pain, physical function, fatigue, sleep, anxiety, depression, and QoL and
- 35 underwent cold- and pressure-based quantitative sensory testing at baseline. Data on
- 36 prescription opioid use over the 12 months prior to study enrollment was used to calculate mean
- 37 daily morphine milligram equivalents (MME). Differences among the three TCM syndromes
- 38 were analyzed by one-way ANOVA followed by Tukey post hoc testing. Two-sample t-tests
- 39 were used to compare SCD and HC groups.

TCM Syndrome Differentiation in SCD

- 40 **Results**: TCM diagnosis criteria classified SCD patients into one of three TCM syndromes: a)
- 41 Equal; b) Deficiency; and c) Stagnation. The Stagnation group exhibited higher pain
- 42 interference, physical dysfunction, nociplastic pain, fatigue, anxiety, depression, MME
- 43 consumption, and lower sleep quality and QoL compared to the Equal group. Few differences
- 44 were observed between HCs and the Equal SCD group across outcomes. Deficiency and
- 45 Stagnation groups were differentiated with observed- and patient-reported clinical46 manifestations.
- 47 **Conclusion**: These findings suggest that TCM-diagnosed syndromes in SCD can be
- 48 differentially characterized using validated objective and patient-reported outcomes. Because
- 49 characteristics of pain and co-morbidities in each SCD patient are unique, targeting specific
- 50 TCM "syndromes" may facilitate treatment effectiveness with a syndrome-based personalized
- 51 treatment plan that conforms to TCM principles. These findings lay the foundation for the
- 52 development of tailored acupuncture interventions based on TCM syndromes for managing pain
- 53 in SCD. Larger samples are required to further refine and validate TCM diagnostic criteria for
- 54 SCD.
- 55
- 56

TCM Syndrome Differentiation in SCD

57 1. Introduction

58

59 Pain in sickle cell disease (SCD) is both common and debilitating. While the pain can be chronic

- 60 in nature, severe acute vaso-occlusive pain crises (VOC) are also present in many of these
- 61 individuals, resulting in recurrent pain episodes that are unpredictable, and frequently require
- 62 hospitalization. As such VOCs are a leading factor lowering the quality of life (QoL) in SCD (1).
- 63 While opioids are the main therapeutic option for managing these events, there are limited
- 64 alternative and effective treatments beyond opioids for these patients (2).
- 65 Acupuncture, a mainline component of traditional Chinese medicine (TCM), has been used for
- 66 over four-thousand years and has been recognized as an effective treatment approach for
- 67 chronic and acute pain conditions (3, 4). Emerging data suggests that acupuncture may
- alleviate pain in both adult and pediatric patients with SCD (5-8). However, a key principle of
- 69 TCM practice is "treatment based on differentiation of syndrome" wherein patients are evaluated
- on a set of diagnostic criteria which can allow classification into a specific TCM syndrome for
- customized treatment. This classification, along with consideration of additional individual
- specific symptom patterns, guides the tailored selection of acupuncture points to treat a
- 73 particular patient (9, 10).
- 74 Two recent studies categorized different TCM patterns in women with pelvic pain (11) or
- 75 fibromyalgia (12). These studies showed that there were 6 TCM patterns in female patients with
- 76 pelvic pain whereas 3 TCM patterns in women with fibromyalgia. There have been no studies
- on TCM syndrome differentiation in SCD. The small sample size and failure to apply TCM
- principles in previous studies of SCD have made it difficult to assess the full potential benefit of
- acupuncture for SCD. For example, it is not known if subgroups of SCD patients exhibit different
- 80 pathogenic features when classified by TCM principles. Identification of different subtypes may
- 81 also be relevant for other therapies in SCD.
- 82 The classic pathophysiology of SCD is polymerization of deoxy sickle hemoglobin which leads
- to a complex interplay of disrupted red blood cell rheology, hemolysis, inflammation, and
- vasculopathy. However, pain in SCD is not well understood, and is characterized by substantial
- heterogeneity in clinical manifestation and underlying pathophysiology (16-24). Notably, clinical
- pain varies in many aspects including quality, intensity, location, and duration under both
- 87 chronic and VOC stages. The onset of VOCs can happen anywhere in the body, with the most
- painful sites being consistent or fixed, and ranging from mild to severe intensity during a specific
- 89 VOC crisis. The frequency of VOCs also varies widely in SCD with a recent systematic review
- 90 reporting a range of 0 to 18.2 per year (25), and variable distribution of VOCs throughout the
- 91 year between individuals. Finally, occurrence of VOCs can also be triggered by various
- 92 multidimensional factor(s), such as temperature, mental stress, dehydration, and/or fatigue.
- 93 These individual differences add significant challenges in the currently unmet management of
- 94 clinical pain in SCD and thus strongly warrants the need for individualized diagnosis and
- 95 personalized treatment. Establishing TCM syndrome differentiation in SCD to help guide
- 96 acupuncture treatment is the current priority.
- 97 Here we report preliminary baseline data from our ongoing randomized sham-controlled trial of
- 98 acupuncture for SCD (ClinicalTrials.gov Identifier: NCT05045820). Patients with SCD were
- 99 classified into three different TCM syndrome groups prior to treatment according to TCM
- 100 principles. Our objective was to investigate differences in patient reported outcome measures

TCM Syndrome Differentiation in SCD

101 (PROMs), quantitative sensory testing (QST), and blood-based assessments across these TCM102 syndrome groups.

103 **2. Methods**

104 **2.1. Participants**

105 Fifty-two patients with SCD (25 male and 27 female), aged 14-73, were enrolled. The main 106 inclusion eligibility criteria included: 1) experiencing chronic pain in the past 6 months or at least 107 one VOC in the past 12 months, 2) no recent history of initiating or adjusting the dose of 108 stimulant medications, 3) willing to maintain current treatments, and 4) willing to not introduce 109 any new medications or treatment modalities for control of pain symptoms during the study. 110 Detailed inclusion and exclusion criteria can be found in Supplementary Table 1. Participants' demographics can be found in Table 1. Twenty-eight pain-free ethnicity-, age- and gender-111 112 matched participants without SCD were enrolled as healthy controls (HCs). A subset of SCD 113 and HCs were matched on age and gender for comparisons of PROMs (n=25-27 each) and 114 QST (n=21-28 each).

115 Patients underwent a TCM diagnostic examination and phenotyping with validated PROMs,

116 QST, and blood tests. HCs completed PROMs, QST, and blood tests. The study was approved

by the Institutional Review Board at Indiana University. All patients provided written informed

118 consent before the study.

119 2.2. TCM diagnosis

- 120 Participants who completed the baseline stage of data collection were then randomized to either
- 121 verum or sham acupuncture for 5 weeks. All data presented here are cross-sectional at
- 122 baseline. Longitudinal results related with acupuncture intervention will be reported elsewhere.
- 123 TCM diagnosis was performed before the treatment by one practitioner with over 15 years of
- 124 clinical experience. This practitioner utilized a standardized procedure with TCM diagnostic
- methods such as "Observation," "Listening and Smelling," "Inquiry," and "Pulse-feeling and
- palpation" (see Supplementary Table 2) (26). Following differentiation of syndrome, patients
- were classified into one of three TCM syndrome groups: a) "Stagnation greater than deficiency"
 (abbreviated as "Stagnation"), b) "Deficiency greater than stagnation" (abbreviated as
- 129 "Deficiency"), and c) "Equal stagnation and deficiency" (abbreviated as "Equal"). Diagnoses
- were confirmed in a blinded manner by a second practitioner with more than 20 years of
- 131 experience.

132 **2.3. Patient reported outcome measures (PROMs)**

133 Pain (pain intensity and interference), physical function, and satisfaction with one's social role

134 were assessed with the PROMIS-29 (27). Neuropathic pain symptoms were evaluated using the

135 PainDETECT (28, 29). The Fibromyalgia Survey Questionnaire (FSQ), which consists of the

136 Widespread Pain Index and the Symptom Severity scale (30, 31), was utilized as a surrogate

137 measure of nociplastic pain. Fatigue and quality of sleep were assessed using the Multi-

dimensional Fatigue Inventory (MFI) (32) and the Pittsburgh Sleep Quality Index (PSQI) (17),

respectively. Anxiety and depression were evaluated using Hospital Anxiety and Depression

140 Scale (HADS) (17).

141 **2.4. Quantitative sensory testing (QST)**

TCM Syndrome Differentiation in SCD

142 QST is an established experimental protocol that examines ascending excitatory and descending

- 143 inhibitory aspects of pain processing by assessing an individual's perceptual response to applied
- stimuli. QST was conducted at up to three different body sites: the primary testing site was the
- 145 most painful area of the body as reported by each patient; the dominant-side ventral forearm,
- and/or the dominant-side upper trapezius muscle as in previous SCD studies (33, 34). For non SCD controls, primary testing sites matched those identified in SCD patients in addition to testing
- 148 at the dominant forearm and/or trapezius.
- 149 <u>Thermal (heat/cold) Detection / Pain Threshold</u> was determined at each testing site using a 150 TCA11 (QST-Lab, France) with a thermal probe in contact with the subject's skin surface. The 151 thermode temperature was increased/decreased from a baseline temperature by adapting to the 152 individual 's own body temperature at a rate of 0.5-1 °C/s. Subjects indicated the thermal detection
- threshold (when they first felt the thermal stimuli) and the pain threshold (when they first felt pain from the thermal stimuli). The average of three trials of each test was used for analysis.
- 154 from the thermal stimuli). The average of three trials of each test was used for analysis.
 155 <u>Mechanical Detection Threshold / Mechanical Pain Threshold</u> was examined using von Frey
 156 monofilaments (Stoelting Co., USA) and calibrated pinprick stimuli (MRC Systems GmbH,
- 157 Germany). Each von Frey monofilament was applied three times in ascending sequence until the 158 stimulus was detected in at least two of the three trials. Then, the next lower von Frey 159 monofilament was applied, and the lowest filament to be detected at least twice was determined 160 as the mechanical detection threshold. The mechanical pain threshold was determined using 161 different pinprick probes applied to the skin surface of each site. Testing started with a stimulation 162 intensity of 8 mN and in each case, the next higher pinprick stimulator was applied until the perception of "touch" changed its quality towards an additional "sharp", "pricking" or "stinging" 163 164 impression. The corresponding intensity represented the first suprathreshold value. Once the first 165 painful stimulus was perceived, the testing direction was changed towards lower stimulus 166 intensities until the first stimulus, when applied to the skin, that was perceived as "blunt" and no 167 longer as being "sharp", "pricking" or "stinging" (subthreshold value). Again, a directional change 168 towards higher intensities occurred and the cycle was repeated until all five supra- and five 169 subthreshold values were found that represent the inflection point to determine the mechanical
- pain threshold.
- 171 <u>Temporal Summation of Pain (TSP)</u> was assessed using single stimulus in triplicate with a 256
- 172 mN pinprick (MRC Systems GmbH) applied to the skin surface of the selected sites, followed by 173 a series of 10 identical stimuli (1 Hz – metronome-guided). TSP was calculated as the average
- pain rating from the series of 10 stimuli minus the average pain rating from the three trials with the single stimulus.
- Pressure Pain Threshold (PPT) / Pressure Pain Tolerance (PPTol) was assessed using a digital,
 handheld, clinical grade pressure algometer (Algometer II, Somedic SenseLab AB, Sweden). The
 pressure was manually increased at a rate of 50 kPa/s (1000 kPa max) until participants indicated
 that the sensation of pressure becomes one of faint pain (PPT) and the maximum pressure pain
 that the participant can tolerate (PPTol), respectively. The average of 3 trials per site was used
 for analysis.
 <u>Conditioned Pain Modulation (CPM)</u>: A sustained pressure pain stimulus was used as the
- conditioning stimulus delivered using a cuff inflator on the gastrocnemius muscle of the nondominant leg to elicit moderate pain (pain rating at 40-60 on a scale of 100) (35, 36). The PPT was then measured 3 times at the primary site and at the dominant trapezius muscle prior to and during the cuff stimulation. Pain ratings were obtained every 15 s prior to and during cuff conditioned stimuli. CPM magnitude was calculated as PPT during cuff pressure minus PPT at baseline .

TCM Syndrome Differentiation in SCD

189

190 **2.5. SCD specific outcomes and morphine milligram equivalent (MME)**

191 The severity and frequency of pain crises were assessed by the Adult Sickle Cell Quality-of-Life 192 Measurement Information System (ASCQ-ME) (37), and the number of patient-reported pain 193 crises in the preceding 12 months was documented, a method which is commonly used in pain 194 research for SCD (18, 38). Pain-related QoL was evaluated using the Pediatric Quality of Life 195 Inventory (PedsQL) (39). The average MME in the preceding 12 months was calculated using 196 prescription data for opioid use before study enrollment. These data were retrieved from 197 patients' medical records and used to calculate the mean daily MME for each opioid, following 198 the Centers for Disease Control recommended MME dose calculation formula (40): {strength 199 per unit X number of units X number of prescriptions X MME conversion factor} / number of

200 days = MME/Day.

201 **2.6. Hematological analysis**

Laboratory blood testing, including complete blood cell count, reticulocytes, and hemoglobin

203 electrophoresis, was conducted on the day of TCM diagnosis (Supplementary Table 5).

204 2.7. Statistical analysis

205 Assessment of differences between TCM syndrome groups was performed using one-way

analysis of variance (ANOVA) followed by Tukey post hoc testing. Two-sample t-tests (two

tailed) were used to compare a subset of SCD patents and matched HCs at baseline. P-values

less than 0.05 were considered significant. All analyses were conducted using GraphPad Prism
 software.

210 **3. Results**

211 **3.1. Demographics**

212 Demographic information is shown in Table 1. TCM groups did not differ in age (p=0.373),

although the Stagnation group presented with a lower median age as compared to other groups.

214 The Deficiency group showed significantly lower weight and body mass index (BMI) as

compared with both the HCs and Stagnation group (p=0.0032; p=0.0002), respectively. The

216 Stagnation group also had more participants numerically with chronic transfusion compared to

the Deficiency and Equal groups. The distribution of hydroxyurea users was also numerically

higher in the Deficiency group compared to the other two groups, but this was not statistically

significant. Each SCD genotype was equally distributed across the three TCM groups.

220 3.2. Clinical Characteristics

221 All three TCM syndrome groups showed increased pain intensity and interference, as well as

symptoms of neuropathic pain, compared to the control group (Table 2). However, only the

223 Stagnation and Deficiency groups reported worse sleep quality, increased levels of fatigue,

anxiety, and depression relative to HCs. In addition, it is worth noting that patients with SCD

also reported pain in more body areas on the Widespread Pain Index and higher overall

fibromyalgia severity. In a subset of SCD patients and matched HCs, the patients reported

comprehensive physiological and psychological dysfunction (Supplementary Table 3),

consistent with previous studies (17, 20, 28, 37).

TCM Syndrome Differentiation in SCD

- 229 Compared to the Equal group, both the Stagnation (p=0.0013) and Deficiency (p=0.0046)
- 230 groups reported increased multi-dimensional pain interference. Both groups also showed higher
- total scores for the FSQ (p=0.0328 Vs Deficiency and p=0.0477 Vs Stagnation) compared to the
- Equal group, while the Stagnation group displayed significantly higher Symptom Severity
- Scores (p=0.0013). Additionally, both the Deficiency and Stagnation groups exhibited worse
- sleep quality than the Equal group (p=0.0293 Vs Deficiency and p=0.0277 Vs Stagnation).
- Furthermore, compared to the Equal group, the Stagnation group showed significantly reduced
- physical function (p=0.0131) and elevated fatigue (p=0.0342), anxiety (p=0.0119), and depression (p=0.0025)
- 237 depression (p=0.0035).
- Notably, the Stagnation (n=6.526 \pm 4.718) and Deficiency (n=5.19 \pm 3.855) groups exhibited a
- higher frequency of pain crises compared to the Equal group (n=1.714 \pm 1.684) (Fig.1A) along
- with higher combined pain crisis recency/severity as assessed by the ASCQ-ME (Fig. 1C), and
- lowest SCD pain-related QoL (Fig 1E), despite no difference in pain severity during crisis
- between groups (Fig. 1D). Additionally, both Stagnation (p=0.0011) and Deficiency (p=0.0029)
- 243 groups had significantly higher opioid usage over the past 12 months compared to the Equal
- 244 group (Fig. 1B).

245 **QST**

- 246 Interestingly, no significant differences between TCM groups on any QST outcomes were
- detected (Table 3), although Deficiency showed an insignificantly elevated MPT (95.38 ± 57.83)
- and HPT (8.940 \pm 2.817) in the forearm whereas Equal group displayed a slightly increased
- 249 PPT (243.9 \pm 94.83) in the trapezius as compared with two other groups for each test.
- 250 Consistent with previous studies, the differences between SCD and their matched healthy
- 251 controls exhibited robust changes across mechanical and thermal sensitivity indexes
- 252 (Supplementary Table 4). In a separate matched subset of SCD patients (n=28) and HCs
- (n=28), the patients exhibited decreased mechanical detection thresholds (p=0.0261 at the
- primary painful site), increased mechanical pain thresholds (primary painful site: p=0.0238;
- forearm: p=0.0358), pressure pain thresholds (primary painful site: p=0.0003; trapezius: p=0.0107), pressure pain tolerance (primary painful site: p=0.0009; trapezius: p = 0.0186), and
- cold pain thresholds (primary painful site: p=0.0332; forearm: p = 0.0250), indicating an overall
- pattern of increased mechanical and thermal sensitivity in SCD.

259 Hematological Indexes

- 260 Fresh blood samples from all patients were analyzed for CBC with differential and hemoglobin
- electrophoresis (refer to Supplementary Table 5). Most hematological indexes did not present
- any differences across the three different TCM syndrome groups. However, the Deficiency and
- 263 Stagnation groups, but not the Equal group, exhibited significantly higher WBC levels compared
- to HCs.

265 **4. Discussion**

- 266 Pain and other symptoms are heterogeneously expressed across SCD patients (41). Indeed,
- the existing literature supports the notion that not all SCD patients have the same underlying
- 268 pathophysiology, similar to other chronic pain disorders (42). The present work describes
- individual characteristics that differ between patients with SCD that are categorized by TCM
- 270 diagnosis.

TCM Syndrome Differentiation in SCD

271 Chronic anemia, recurrent acute vaso-occlusive, and chronic pain are common manifestations 272 of SCD caused by complex pathophysiology from hemoglobin S polymerization, hemolysis, 273 endothelial dysfunction, and vaso-occlusion (43). According to the theory of TCM, symptoms 274 such as low energy or excessive fatigue, sallow complexion, and pale lips and nails, which are 275 caused by chronic anemia, are considered clinical manifestations of deficiency of both gi and 276 blood (9). Recurrent pain in the chest, waist, back, and limbs, including severe pain and swelling 277 of hands and feet caused by capillary microthrombosis, are considered clinical manifestation of 278 blood stasis blocking meridians (44). As such, from a TCM perspective, the pathogenesis of 279 SCD primarily manifests as a deficiency of both gi and blood, accompanied by blood stasis 280 obstructing the meridians. Many individuals across our three TCM syndrome groups 281 consistently displayed anemic manifestations such as pale lips and nails. The features of tongue 282 observed in the TCM syndrome groups mainly reflected blood stasis-related manifestations, 283 such as purple/dark spots in the tongue body. Many individuals across all TCM syndrome 284 groups also presented with weak or thin wiry pulse, with more individuals in the Stagnation 285 group who exhibited knotted pulse features indicating stagnation syndrome. These are consistent with characteristics of the "Bi Syndrome" that has insufficient righteousness and 286 287 obstruction of meridians by pathogenic factors (45). Moreover, because of its severe pain as the 288 signature of the condition, it may be considered as a form of "Painful Bi" and "Blood Stasis Bi" within the scope of "Bi Syndrome" as the intense pain is mainly caused by the obstruction of 289 290 meridians by blood stasis.

291 Individuals with SCD enrolled in our study were classified into three main TCM syndromes:

292 Equal, Deficiency, and Stagnation. These syndromes were primarily differentiated on the

293 characteristics of pain (e.g., quality, intensity, onset, time of duration), physical dysfunction (e.g.,

fatigue/weak), followed by other symptoms (e.g., ease of sweating, facial complexion, voice, lips

or nails, characteristics of "Tongue" and "Pulses"). See Supplementary Table 2 for a full

296 description of diagnostic criteria.

297 The three TCM syndrome groups were differentiated in patient-reported outcomes that were 298 related to pain and somatic symptoms, such as fatigue, physical function, sleep disturbance, as 299 well as SCD related outcomes, including VOC specific pain and frequency and opioid 300 consumption. Noticeably, the Stagnation and Deficiency groups showed greater nociplastic pain 301 features and worse sleep compared to the Equal group. The Stagnation group also exhibited 302 the lowest QOL scores compared to the Equal group. Additionally, the Stagnation group also 303 displayed worse physical dysfunction, and higher levels of anxiety and depression as compared 304 to the other two groups. These results suggest that the Stagnation group may have more 305 nociplastic pain symptoms and other characteristics (sleep/fatigue/mood) that are commonly 306 amplified in fibromyalgia, the canonical nociplastic pain condition. Interestingly, the three groups 307 did not differ significantly in neuropathic pain or QST outcomes (see below). These data 308 suggest that the three TCM groups did not differ with respect to nociceptive and neuropathic 309 pain. Notably, both the Stagnation and Deficiency groups also had more intense pain-related 310 clinical symptoms (Table 2) but differed in the duration and character of pain at the chronic 311 stage of SCD and during acute SCD episodes (Fig.1).

312

With respect to SCD pathology, both Stagnation and Deficiency groups presented with higher frequency of VOCs (Fig. 1A and C) and opioid usage (MME) compared to Equal group (Fig. 1B). This increase in opioid requirement in the Stagnation group is consistent with nociplastic pain patients having reduced endogenous opioid efficacy (46). Importantly, the Stagnation group also reported the most frequent, intense, and sudden onset of VOCs as their main

TCM Syndrome Differentiation in SCD

- 318 symptoms/signs, whereas the chief complaint of Deficiency group was more reflected in fatigue.
- 319 weakness and chronic pain as summarized in Supplementary Table 2. This may explain the
- 320 difference in general overall pain interference reported across the TCM syndrome groups, with
- 321 the Stagnation group reporting the highest pain interference.
- 322

323 We also observed differences between the Deficiency and other two groups based on pain 324 presentation. Noticeably, chronic pain was not always present and was sometimes absent in 325 individuals of both Equal and Stagnation groups. The Deficiency group experienced more 326 profound chronic pain along with Qi and Blood deficiency syndrome as reported in 327 Supplementary Table 2. This long-term persistent pain with recurrent VOCs in the Deficiency 328 group could be related to the significantly lower weight and BMI (Table 1) and RBC 329 (Supplementary Table 5) as compared with Stagnation, which may further explain other co-330 existing symptoms such as intense fatigue, weakness, and profuse sweating that are also

- 331 associated with "deficiency" in TCM (Supplementary Table 2).
- 332

333 The symptoms that may reflect a higher prevalence of "blood stasis" were more prominent in the 334 Stagnation group whereas symptoms of more "blood and Qi Deficiency" were found in the 335 Deficiency group from the TCM perspective. These data suggest a more personalized 336 acupuncture treatment with selected acupoints and corresponding needling manipulations 337 ("reinforce" / "reduce" / "non-reinforce or reduce") may be needed to treat individual patients 338 based on selected acupoints based on both TCM syndrome differentiation and individual symptoms.

339

340 341 Interestingly, the SS type of SCD seems to be equally distributed across the three TCM 342 syndrome groups. The SCD subtype HbSS is known to be a more severe form of the disease 343 on average compared to the HbSC genotype (47, 48), and it is positively correlated with the 344 degree of psychological symptoms experienced by the patient (48, 49). More importantly, even 345 though the WBC % was lower in the Equal group, this group presented with comparable levels 346 of all pathological hematological indexes as compared to the two other groups (Supplementary 347 Table 5). This finding may suggest that the less severe clinical symptoms presented in the 348 individuals of Equal group are not related to the SCD genotype but may be associated with 349 other underlying pathophysiological mechanisms in these patients.

350

351 In an effort to examine participant differences in touch and pain sensitivity we also conducted a 352 battery of QST using methods that have been widely applied across various chronic pain 353 conditions. Existing literature documenting altered QST thresholds using fixed testing sites in 354 SCD has identified increased sensitivity in response to thermal/mechanical painful stimuli 355 compared to non-SCD pain-free HCs (17, 33, 34, 50). However, pain in SCD can occur 356 anywhere in the body or sometimes throughout the entire body during an active crisis, and the 357 features and locations of pain can vary significantly among individuals. In our study, patients 358 reported a variety of painful locations including: the lower- and mid- to upper-back, hips, 359 shoulders, thighs, knees, and lower extremities. This occurred during both the steady phase and 360 active crises. Moreover, the painful locations during acute pain episodes under VOC could also 361 be exaggerated or replaced by more painful regions elsewhere (e.g., chest, large joints) or a 362 combination of locations. We did not detect any significant differences in QST outcomes across 363 the three TCM patterns. This suggests that our TCM syndromes were not different across 364 nociceptive experimental pain stimuli. Of note, the 3 TCM groups also did not differ in neuropathic pain symptoms assessed with the PainDETECT questionnaire. As mentioned 365 366 above, the Stagnation and Deficiency groups displayed higher nociplastic pain symptoms than

TCM Syndrome Differentiation in SCD

the Equal groups which was driven mostly by the Symptom Severity sub-scale for the

368 Stagnation group. Overall, these data may suggest involvement of nociplastic pain mechanisms 369 in SCD moreso in the Stagnation and Deficiency groups than the Equal group.

370 Our study has limitations. This is a cross-sectional study: therefore, causation cannot be 371 determined. For example, the two TCM patterns ("Stagnation" and "Deficiency") had significantly 372 higher opioid consumption (MME) than "Equal" pattern before enrollment, as such we could not 373 determine if there was a relationship between the level of opioid consumption and TCM pattern. 374 Moreover, we could not gauge the potential effects of this medication usage on TCM patterns. 375 The consistent performance of accurate diagnosis relies on the clinical experience of the 376 practitioner and requires training. Our diagnosis criteria were also established based on the 377 enrolled SCD patients in this study and therefore may not be a definitive reference for these 378 results. In addition, the 3 TCM syndromes did not differentiate in other objective parameters 379 such as laboratory exams or QST but primarily in patient-reported outcomes. Thus, this study 380 lacks objective markers associated with different TCM patterns. Future studies should consider 381 a more comprehensive diagnosis regimen at different stages of the disease (e.g., patients at 382 active VOC stages can have different subtypes of Stagnation). The diagnosis criteria should be 383 further validated and standardized in a larger sample size.

384

385 To our knowledge, this is the first and largest clinical trial investigating TCM syndrome diagnoses in SCD. Optimal therapeutic effects could be achieved by administering the TCM-386 387 guided treatment protocol with the appropriate acupuncture points and needling manipulations 388 (51). The implementation of TCM syndrome diagnosis can not only guide the acupuncture 389 treatment but also other alternative treatment such as herbology to facilitate consistent and 390 personalized integrative care. The present study provides a novel and objective clinical 391 relevance for TCM diagnosis and lays the foundation for assessing the outcomes of TCM-392 guided interventions for managing pain not only in SCD but also other clinical population with 393 complex pathophysiology and large heterogeneity needing individualized treatment for optimal 394 clinical outcomes. More in-depth investigations are warranted to enhance evidence-based 395 integrative and complementary pain management in challenging clinical populations such as 396 SCD.

397 5. Author Contributions

398 Y.W., D.D.W., and A.Q.P. analyzed, validated, and interpreted the data; Y.W. drafted the

399 manuscript; D.D.W., S.E.H., and R.E.H. revised the manuscript and helped with data

400 interpretation; Y.W. and A.R.O. directed patient recruitment; Y.W. designed the study,

401 supervised the overall study performance, and edited the manuscript.

402 6. Acknowledgement

403 The authors would like to thank Brandon Alec Reyes, Tyler James Barret, Nayana Dutt, Payton 404 Mittman, and Bea Paras for assisting with data collection; Candice Debats and Justin Smith for

assisting with chart info retrieval and data summarization; and Siddhi Gandhi, Charanjit Kaur,

and Veena Vijayan for data management and validation, as well as all the providers affiliated

407 with Indiana University Health and Indiana Hemophilia & Thrombosis Center for patient referral

to this study. The authors also thank Indiana University Clinical Research Center and Indiana

409 University Research MRI Center for resource support.

410 **7. Conflict of interest**

TCM Syndrome Differentiation in SCD

- 411 S.H.E. has consulted for Aptinyx, Memorial Sloan Kettering Cancer Institute, University of North
- 412 Carolina-Chapel Hill, and University of Glasgow and received grant funding from NIH, Arbor
- 413 Medical Innovations, and Aptinyx. R.E.H has consulted for Pfizer, Aptinyx Inc. and has received
- grant funding from Pfizer, Aptinyx, and Cerephex. and National Institutes of Health (NIH). The
- 415 remaining authors declare no competing interests.

416 8. Funding Support

- 417 This work was supported by NIH K99/R00 award (Grant # 4R00AT010012) and Indiana
- 418 University Health Indiana University School of Medicine Strategic Research Initiative funding
 419 to Y.W.
- 11) (0)
- 420

TCM Syndrome Differentiation in SCD

421 Tables/Figures

Table 1. Demographics. Demographic information of participants in each TCM group and HCs
 were collected during the screening visit. The demographic indexes did not differ across groups
 except that weight and body mass index was significantly lower in Deficiency compared to HCs
 and Stagnation.

426 **Table 2. TCM Groups Differed on Patient Reported Outcomes.** Patient reported outcomes in

- related with pain (intensity and interference), neuropathic and nociplastic pain syndromes,
- 428 physical function, sleep, and fatigue were assessed with PROMIS-29, PainDETECT,
- Fibromyalgia Survey Questionnaires, the Pittsburgh Sleep Quality Index, Multi-dimensional
- 430 Fatigue Inventory, as well as Hospital Anxiety and Depression Scale. Patients with SCD
- reported increased pain, physiological and psychological dysfunction as compared with HCs.
- The Stagnation and Deficiency groups displayed worse outcomes than the Equal group.

433 Figure 1. SCD Patients Differed on VOC, MME and QoL Across TCM Groups. The severity

and frequency of pain crises and SCD Pain-related QoL were assessed by the ASCQ-ME (**C**)

- 435 and PedsQL (E), respectively while the number of patient-reported pain crises in the preceding
- 436 12 months was also shown (**A**). The average MME in the preceding 12 months was calculated
- 437 using: {strength per unit X number of units X number of prescriptions X MME conversion factor}
- 438 / number of days = MME/Day. Stagnation and Deficiency groups exhibited a higher frequency of 439 pain crises compared to the Equal group ($n=1.714 \pm 1.684$) (**A and C**) and lowest SCD pain-
- related QoL (**E**). No difference in pain severity during crisis between groups (**D**). Importantly,
- both Stagnation and Deficiency groups had significantly higher opioid usage over the past 12
- 442 months compared to the Equal group (**B**).
- 443
 Table 3. TCM Groups Did not Differ on QST. No significant differences between TCM groups

444 on any QST outcomes were detected although Deficiency showed an insignificantly elevated

445 Mechanical Pain Threshold and Heat Pain Threshold in the forearm whereas Equal group 446 displayed a slightly but insignificantly increased Pressure Pain Threshold in the trapezius as

- 447 compared with two other groups.
- 448 **Supplementary Table 1**. Study Eligibility Criteria.
- 449 **Supplementary Table 2**. TCM Diagnosis Criteria.
- 450 **Supplementary Table 3**. Patient with SCD Differed with HCs in Patient Reported Outcomes.
- 451 **Supplementary Table 4**. Patient with SCD Differed with HCs in QST.
- 452 **Supplementary Table 5**. Patient with SCD Differed with HCs in Hematological Measures.
- 453
- 454
- 455

TCM Syndrome Differentiation in SCD

456 **References**

Osunkwo, I., Andemariam, B., Minniti, C.P., Inusa, B.P.D., El Rassi, F., Francis-Gibson,
 B., et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease
 management strategies: Results from the international Sickle Cell World Assessment Survey
 (SWAY). Am J Hematol. 2021;96(4):404-17.

Sagi, V., Mittal, A., Tran, H., Gupta, K. Pain in sickle cell disease: current and potential
 translational therapies. Transl Res. 2021;234:141-58.

3. Vickers, A.J., Cronin, A.M., Maschino, A.C., Lewith, G., MacPherson, H., Foster, N.E., et
al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med.
2012;172(19):1444-53.

466 4. Xiang, A., Cheng, K., Shen, X., Xu, P., Liu, S. The Immediate Analgesic Effect of 467 Acupuncture for Pain: A Systematic Review and Meta-Analysis. Evid Based Complement 468 Alternat Med. 2017;2017:3837194.

469 5. Williams, H., Tanabe, P. Sickle Cell Disease: A Review of Nonpharmacological
470 Approaches for Pain. J Pain Symptom Manage. 2016;51(2):163-77.

471 6. Lu, K., Cheng, M.C., Ge, X., Berger, A., Xu, D., Kato, G.J., et al. A retrospective review

- of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis
 from a single institution. Clin J Pain. 2014;30(9):825-30.
- Tsai, S.L., McDaniel, D., Taromina, K., Lee, M.T. Acupuncture for Sickle Cell Pain
 Management in a Pediatric Emergency Department, Hematology Clinic, and Inpatient Unit.
 Medical Acupuncture. 2015;27(6):510-4.
- 477 8. Li, H., Patil, C.L., Molokie, R.E., Njoku, F., Steffen, A.D., Doorenbos, A.Z., et al.
 478 Acupuncture for chronic pain in adults with sickle cell disease: a mixed-methods pilot study.
 479 Acupunct Med. 2021;39(6):612-8.

480 9. Zhang, F. The Pattern Identification and Treatment of Acumoxatherapy. Beijing: 2000;
481 2000.

482 10. Flaws, B., Sionneau, P. The Treatment of Modern Western Medical Diseases with
483 Chinese Medicine. Boulder, CO: Blue Poppy Press; 2002.

484 11. Arentz, S., Smith, C., Redmond, R., Abbott, J., Armour, M. A cross-sectional study of 485 traditional Chinese medicine practitioner's knowledge, treatment strategies and integration of 486 practice of chronic pelvic pain in women. BMC Complement Med Ther. 2021;21(1):174.

Mist, S.D., Wright, C.L., Jones, K.D., Carson, J.W. Traditional Chinese medicine
 diagnoses in a sample of women with fibromyalgia. Acupunct Med. 2011;29(4):266-9.

Deng, G., Mao, J.J. Acupuncture to Reduce Opioid Consumption in Patients with Pain:
 Getting to the Right Points. Pain Med. 2019;20(2):207-8.

491 14. Zheng, Z., Gibson, S., Helme, R.D., Wang, Y., Lu, D.S., Arnold, C., et al. Effects of
492 Electroacupuncture on Opioid Consumption in Patients with Chronic Musculoskeletal Pain: A
493 Multicenter Randomized Controlled Trial. Pain Med. 2019;20(2):397-410.

Hamza, M.A., White, P.F., Ahmed, H.E., Ghoname, E.A. Effect of the frequency of
transcutaneous electrical nerve stimulation on the postoperative opioid analgesic requirement
and recovery profile. Anesthesiology. 1999;91(5):1232-8.

Campbell, C.M., Carroll, C.P., Kiley, K., Han, D., Haywood, C., Jr., Lanzkron, S., et al.
Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with
sickle cell disease to healthy matched controls. Pain. 2016;157(4):949-56.

500 17. Campbell, C.M., Moscou-Jackson, G., Carroll, C.P., Kiley, K., Haywood, C., Jr.,

Lanzkron, S., et al. An Evaluation of Central Sensitization in Patients With Sickle Cell Disease. J
 Pain. 2016;17(5):617-27.

503 18. Darbari, D.S., Hampson, J.P., Ichesco, E., Kadom, N., Vezina, G., Evangelou, I., et al.

504 Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity 505 in Sickle Cell Disease. J Pain. 2015;16(11):1077-86.

TCM Syndrome Differentiation in SCD

506 19. Belfer, I., Youngblood, V., Darbari, D.S., Wang, Z., Diaw, L., Freeman, L., et al. A GCH1
507 haplotype confers sex-specific susceptibility to pain crises and altered endothelial function in
508 adults with sickle cell anemia. Am J Hematol. 2014;89(2):187-93.

Brandow, A.M., Stucky, C.L., Hillery, C.A., Hoffmann, R.G., Panepinto, J.A. Patients with
sickle cell disease have increased sensitivity to cold and heat. Am J Hematol. 2013;88(1):37-43.
Cataldo, G., Rajput, S., Gupta, K., Simone, D.A. Sensitization of nociceptive spinal
neurons contributes to pain in a transgenic model of sickle cell disease. Pain. 2015;156(4):72230.

514 22. Hillery, C.A., Kerstein, P.C., Vilceanu, D., Barabas, M.E., Retherford, D., Brandow, A.M.,
515 et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell
516 disease. Blood. 2011;118(12):3376-83.

Vincent, L., Vang, D., Nguyen, J., Gupta, M., Luk, K., Ericson, M.E., et al. Mast cell
activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013;122(11):1853-62.
Bogdanova, A., Kaestner, L., Simionato, G., Wickrema, A., Makhro, A. Heterogeneity of

520 Red Blood Cells: Causes and Consequences. Front Physiol. 2020;11:392.

- Zaidi, A.U., Glaros, A.K., Lee, S., Wang, T., Bhojwani, R., Morris, E., et al. A systematic
 literature review of frequency of vaso-occlusive crises in sickle cell disease. Orphanet J Rare
 Dis. 2021;16(1):460.
- Lufen, W. Diagnosis of Traditional Chinese Medicine: Shanghai College of Traditional
 Chinese Medicine; 2002.
- 526 27. Curtis, S., Brandow, A.M. Responsiveness of Patient-Reported Outcome Measurement
 527 Information System (PROMIS) pain domains and disease-specific patient-reported outcome
 528 measures in children and adults with sickle cell disease. Hematology Am Soc Hematol Educ
 529 Program. 2017;2017(1):542-5.
- 530 28. Brandow, A.M., Farley, R.A., Panepinto, J.A. Neuropathic pain in patients with sickle cell 531 disease. Pediatr Blood Cancer. 2014;61(3):512-7.
- 532 29. Freynhagen, R., Baron, R., Gockel, U., Tolle, T.R. painDETECT: a new screening 533 questionnaire to identify neuropathic components in patients with back pain. Curr Med Res 534 Opin. 2006;22(10):1911-20.
- 535 30. Clauw, D.J. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-55.
- 536 31. Dudeney, J., Law, E.F., Meyyappan, A., Palermo, T.M., Rabbitts, J.A. Evaluating the 537 psychometric properties of the Widespread Pain Index and the Symptom Severity scale in youth 538 with painful conditions. Can J Pain. 2019;3(1):137-47.
- 539 32. Lin, J.M., Brimmer, D.J., Maloney, E.M., Nyarko, E., Belue, R., Reeves, W.C. Further
 540 validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul
 541 Health Metr. 2009;7:18.
- 542 33. Darbari, D.S., Vaughan, K.J., Roskom, K., Seamon, C., Diaw, L., Quinn, M., et al.
- 543 Central sensitization associated with low fetal hemoglobin levels in adults with sickle cell 544 anemia. Scand J Pain. 2017;17:279-86.
- 545 34. Miller, R.E., Brown, D.S., Keith, S.W., Hegarty, S.E., Setty, Y., Campbell, C.M., et al. 546 Quantitative sensory testing in children with sickle cell disease: additional insights and future 547 possibilities. Br J Haematol. 2019;185(5):925-34.
- Standard Sta
- 551 36. Schoen, C.J., Ablin, J.N., Ichesco, E., Bhavsar, R.J., Kochlefl, L., Harris, R.E., et al. A

novel paradigm to evaluate conditioned pain modulation in fibromyalgia. J Pain Res.

553 2016;9:711-9.

TCM Syndrome Differentiation in SCD

- 554 37. Treadwell, M.J., Hassell, K., Levine, R., Keller, S. Adult sickle cell quality-of-life 555 measurement information system (ASCQ-Me): conceptual model based on review of the 556 literature and formative research. Clin J Pain. 2014;30(10):902-14.
- 38. Wang, Y., Hardy, S.J., Ichesco, E., Zhang, P., Harris, R.E., Darbari, D.S. Alteration of
 grey matter volume is associated with pain and quality of life in children with sickle cell disease.
 Transl Res. 2022;240:17-25.
- 39. Panepinto, J.A., Torres, S., Bendo, C.B., McCavit, T.L., Dinu, B., Sherman-Bien, S., et
 al. PedsQL sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer.
 2013;60(8):1338-44.
- 40. Dowell D, R.K., Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for
 Prescribing Opioids for Pain United States, 2022. MMWR Recomm Rep. 2022;71(No. RR3):1–95.
- 566 41. McClish, D.K., Smith, W.R., Dahman, B.A., Levenson, J.L., Roberts, J.D., Penberthy, 567 L.T., et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain.
- 568 2009;145(1-2):246-51.
- 569 42. Fillingim, R.B. Individual differences in pain: understanding the mosaic that makes pain 570 personal. Pain. 2017;158 Suppl 1(Suppl 1):S11-S8.
- 571 43. Sundd, P., Gladwin, M.T., Novelli, E.M. Pathophysiology of Sickle Cell Disease. Annu 572 Rev Pathol. 2019;14:263-92.
- 573 44. Maciocia, G. The Foundations of Chinese Medicine. Singapore: Longman Singapore 574 Publishers (Pte) Ltd; 1994.
- 45. Wang, C., Shen, P., Hu, Y. Practical Chinese Medicine Rheumatology (Second Edition).
 Beijing: People's Health Publishing House; 2009.
- 577 46. Schrepf, A., Harper, D.E., Harte, S.E., Wang, H., Ichesco, E., Hampson, J.P., et al.
 578 Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain.
 579 2016;157(10):2217-25.
- 580 47. Konotey-Ahulu, F.I.D. The sickle cell disease patient : natural history from a clinico-
- epidemiological study of the first 1550 patients of Korle Bu Hospital Sickle Cell Clinic. London:
 Macmillan; 1991. xix, 643 P. p.
- 48. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H., et al.
 Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med.
 1994;330(23):1639-44.
- 586 49. Scott, K.D., Scott, A.A. Cultural Therapeutic Awareness and Sickle Cell Anemia. Journal 587 of Black Psychology. 1999;25(3):316-35.
- 588 50. Carroll, C.P., Lanzkron, S., Haywood, C., Jr., Kiley, K., Pejsa, M., Moscou-Jackson, G.,
- et al. Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. Am J Prev Med.
 2016;51(1 Suppl 1):S69-77.
- 591 51. Xinnong, C. Chinese Acupuncture and Moxibustion. 4th ed: Foreign Languages Press; 592 2019.
- 593

Table 1 Demographics

Subjects' characteristics (n=52)	TCM#1 (Equal) (n=13)	TCM#2 (Deficiency) (n=20)	TCM#3 (Stagnation) (n=19)	Healthy (n=28)
Age (year), median (range)	37 (14-49)	36.5 (18-73)	30 (14-58)	33 (14-65)
Female, n (%)	5 (38.5)	9 (45.0)	12 (63.2)	17 (60.7)
Height (cm), median (range)	173.4 (161.5 - 185.2)	168.9 (150.4-184.3)	168.1 (154.7 - 181.1)	168.15 (154.8 - 184.4)
Weight (kg), median (range)	73.4 (54.4 - 112.6)	62.9 (37.6-106.2) **##	80.8 (56.8 - 123.5)	75.8 (50.4 - 112.4)
Body mass index, median (range)	23.7 (19.3 - 33.7)	20.6 (16.5 - 35.6) **###	28.6 (19.7 - 35.6)	26.7 (19 - 42.8)
SCD type diagnosis (n=52)				
SS or Sβ0/SC/Sβ+ thalassemia	7/6/0	15/1/4	11/7/1	N/A
(n / n / n)				
Hematological treatment (n=52)				
Chronic transfusion therapy, n	0	3 (15)	1 (7)	N/A
(%)				
Hydroxyurea, n (%)	7 (53.8)	14 (70)	8 (53.8)	N/A

****p< 0.01** compared with Healthy, **##p< 0.01** compared with Stagnation, **###p< 0.001** compared with Stagnation

Table 2. TCM Groups Differed on Patient Reported Outcomes

Patient-reported outcomes	Score name (value range)	TCM#1 (Equal) (Mean±SD)	TCM#2 (Deficiency) (Mean±SD)	TCM#3 (Stagnation) (Mean±SD)	Healthy (Mean± SD)
PainDETECT	Total score (7-47)	18.92±3.825****	18.25±8.095****	22.47±9.172****	7.273±0.8013
	Pain Intensity (0-10)	3.583±2.314****	5.6±1.639****#	5.75±1.88****##	0.5000 ± 1.244
PROMIS-29	Pain Interference (4-20)	11.50±5.072 ****	16.63±5.830****##	17.27±3.369****##	4.781±1.791
	Physical function (4-20)	6.417±1.975	8.438±3.949***	10.00±4.536 ****#	4.333±1.407
	Satisfaction with social role (4-20)	14.42±5.368	7.875±3.757 ****####	9.933±4.574****#	17.50±3.556
Fibromyalgia Survey Questionnaire	Widespread Pain Index (0-19)	4.667±4.228**	7.563±4.066****	6.267±4.496****	0.6061±1.391
	Symptom Severity Score (0-12)	2.917±1.832	5.313±3.516****	6.667±2.637****##	1.606 ± 1.999
	Total Score (0-31)	7.583±5.632*	12.88±6.879****#	12.67±5.367****#	2.212 ± 3.090
Pittsburgh Sleep Quality Index (PSQI)	Global PSQI Index	12.17±8.032	20.73±9.293***#	20.80±8.046 ***#	10.91±6.760
Multi-dimensional Fatigue Inventory (MFI)	Total MFI Score (0-100)	45.58±9.395	56.00±19.73*	61.60±15.29***#	41.91±13.46
Hospital Anxiety and	Anxiety Score (0-21)	4.250±2.417	6.250±3.924*	8.714±5.413 ****#	2.719±2.679
Depression Scale	Depression Score (0-21)	2.833±2.038	5.250±3.697 **	6.714±3.750****###	1.938±1.795

*p< 0.05 compared with Healthy, **p< 0.01 compared with Healthy, ***p< 0.001 compared with Healthy, ***p< 0.0001 compared with Healthy, #p< 0.05 compared with Equal, ##p< 0.01 compared with Equal, ##p< 0.001 compared with Equal.

Table 3. TCM Groups Did not Differ on QST

Score name	TCM#1 (Equal) (Mean±SD)	TCM#2 (Deficiency) (Mean± SD)	TCM#3 (Stagnation) (Mean±SD)	Healthy (Mean± SD)
Mechanical Detection Threshold (forearm)	0.2673±0.1852	0.3346±0.6821	0.4193±0.2986	0.4276±0.2605
Mechanical Pain Threshold (forearm)	61.00±61.01	95.38±57.83	70.68±49.89	93.64±85.84
Temporal Summation (forearm)	14.31±11.94	12.46±9.314	15.13±12.70	11.54 ± 11.90
Cold Detection Threshold (forearm)	-1.983±0.7309	-1.947±0.7643	-2.907±1.328	-2.400±1.147
Cold pain Threshold (forearm)	-8.864±7.710	-10.19±7.673	-9.147±5.725	-14.41±9.501
Heat Detection Threshold (forearm)	3.508±1.179	3.233±1.174	3.820±2.474	3.424±1.710
Heat pain Threshold (forearm)	6.892±4.024	8.940±2.817	7.927±3.499	8.038±3.296
Pressure Pain Threshold (Trapezius)	243.9±94.83	215.1±100.5	219.5±76.08	271.8±122.8
Pressure Pain Tolerance (Trapezius)	336.9±145.5	324.0±124.8	386.6±175.7	439.6±244.0
Conditioned Pain Modulation (Trapezius)	46.67±56.90	49.21±101.8	70.71±105.2	35.53±54.81

Fig. 1 SCD Patients Differed on VOC, MME and QoL Across TCM Groups



Supplementary Table 1. Study Eligibility Criteria

Inclusion Criteria

Any gender

• 14-17 (Adolescents) and 18-80 (Adults) years old

• Right-handed

• Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months.

• Subjects with ongoing VOC (or hospitalization during enrollment will not be scheduled for QST and MRI sessions, other scheduled sessions will remain.

• Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits.

• Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupuncture treatments up to two times weekly for 5 weeks as scheduled.

Fluent in English and capable of giving written informed consent.

Exclusion Criteria

Subjects with Covid-19 suspicion or confirmation

• Recent/ongoing alternative pain management with acupuncture or acupuncture-related techniques within the last 6-months.

• Presence of a known coagulation abnormality: Thrombocytopenia (mild thrombocytopenia with a platelets range of 51,000-100,000/ul will be further evaluated for inclusion consideration), or bleeding diathesis that may preclude the safe use of acupuncture.

 Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain or any other chronic pain condition with pain greater than sickle pain.

Recent (30 days) initiation or dose adjustment of stimulant medications, such as those used to treat ADD/ADHD (e.g., amphetamine/dextroamphetamine [Adderall®], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil).

• Disease/Condition History: Head injury with substantial loss of consciousness, peripheral neuropathy of known cause that interferes with activities of daily living, known non-SCD related Severe psychiatric illnesses (e.g. current schizophrenia, major depression with suicidal ideation), and/or significant visual, motor, or auditory impairment that would interfere with ability to perform study visits-related activities

• Contraindications to MRI scans includes but are not limited to: surgical clips, surgical staples, metal implants, cardiac rhythmic disorders, seizure disorders, and certain metallic dental material will not be scheduled for MRI visits.

• Exclusion for partial QST or MRI scan session: History vascular surgery in lower limbs or current lower limb vascular dysfunction will not receive conditioned pressure pain stimuli in the lower limb.

• Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's sickle disease; current involvement in out-of-court settlements for claims pertinent to the subject's sickle disease; or currently receiving monetary compensation as a result of any of the above.

• Participation of other studies: Concurrent participation in other therapeutic trials with overlapping research purposes.

Pregnant or nursing.

Supplementary Table 2. TCM Syndrome Diagnostic Criteria in SCD

	TCM#1	TCM#2	TCM#3
Diagnosis	Equal Deficiency and Stagnation	Deficiency Greater Than Stagnation	Stagnation Greater Than Deficiency
Main Symptoms/signs	Mild or moderate chronic pain only, or infrequent acute pain only, or chronic pain with infrequent acute pain Tongue body: light red or slightly pale, or with purple spots Pulses: thin, wiry, or normal	Group Symptoms 1: Fatigue; weakness; shortness of breath; worsening after exertion; dull, sallow or pale complexion; pale lips and nails Group Symptoms 2: chronic pain only, or chronic pain that gets progressively worse before VOC; dull, or stabbing or sharp pain; mild or moderate or severe pain level; pain better by pressing Tongue body: pale or pale with purple spots Pulses: thin, weak and /or deep	Group symptoms 1: Chronic pain with frequent sudden onset of acute pain; stabbing or sharp pain; moderate or severe pain level; pain aggravated by pressing Group symptoms 2: Fatigue; weakness; shortness of breath; worsening after exertion; dull, sallow or pale complexion; pale lips and nails Tongue body: pale with purple spots, or dark Pulses: wiry, or choppy or knotted
TCM diagnostic Criteria	Meet neither TCM#2 nor TCM#3	 Meet: Four or more in group symptoms 1; two or more in group symptoms 2 Or Three or more in group symptoms 1; two or more symptoms in group symptoms 2; Tongue and pulse signs 	 Meet: Three or more symptoms in group symptoms 1; two or more in group symptoms 2 Or Two or more in group symptoms 1; two or more in group symptoms 2; tongue and pulse signs

Supplementary Table 3. Patient with SCD Differed with HCs in Patient Reported Outcomes

Patient-reported outcomes	Score name (value range)	Healthy (Mean±SD) (n=28)	Matched SCD (Mean± SD) (n=28)	P value
PainDETECT	Total score (7-47)	7.259 ± 0.8130	15.11±10.51	<0.0007 ***
PROMISE-29	Pain Intensity (0-10)	0.3846±1.169	4.500±2.232	<0.0001 ****
	Pain Interference (4-20)	4.731±1.867	12.54±7.201	<0.0001 ****
	Physical function (4-20)	4.333±1.544	9.852±4.312	<0.0001 ****
	Satisfaction with social role (4-20)	17.77±3.278	8.885±5.694	<0.0001 ****
	Widespread Pain Index (0-19)	0.4444 ± 1.188	6.259±3.996	<0.0001 ****
Fibromyalgia Survey Questionnaire	Symptom Severity Score (0-12)	1.556±1.928	5.296±2.399	<0.0001 ****
	Total Score (0-31)	2.000 ± 2.746	9.333±5.704	<0.0001 ****
Pittsburgh Sleep Quality Index (PSQI)	Global PSQI Index (0-47)	9.880±5.681	20.52±6.325	<0.0001 ****
Multi-dimensional Fatigue Inventory	Total Score (0-100)	40.85±12.95	53.92±17.90	0.0062 **
Hospital Anxiety and	Anxiety Score (0-21)	2.680±2.839	18.16±19.38	0.0007 ***
Depression Scale	Depression Score (0-21)	2.040 ± 1.904	7.200±6.069	0.0011 **

*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001

Supplementary Table 4. Patient with SCD Differed with HCs in QST

Score name	Matched Healthy (n=28)	Matched SCD (n=28)	P value
	(Iviean ± SD)	(Iviean ± SD)	
Mechanical Detection Threshold (Forearm)	0.4435±0.2664	0.3140±0.2759	0.1152
Mechanical Detection Threshold (Primary site)	0.5368±0.5209	0.2596±0.2365	0.0261*
Mechanical Pain Threshold (Forearm)	102.5±91.86	58.56 ± 46.48	0.0358*
Mechanical Pain Threshold (Primary site)	109.8 ± 64.27	66.37±79.31	0.0238*
Mechanical Temporal Summation (Forearm)	11.72±12.22	12.30 ± 9.162	0.8571
Mechanical Temporal Summation (Primary site)			
Cold Detection Threshold (compared to BL skin temperature) (Forearm)	-2.396±1.191	-2.354 ± 1.124	0.9067
Cold Detection Threshold (compared to BL skin temperature) (Primary site)	-2.723±2.065	-2.900 ± 1.724	0.7631
Cold pain Threshold (compared to BL skin temperature) (Forearm)	-14.74±9.513	-9.082±5.309	0.0250*
Cold pain Threshold (compared to BL skin temperature) (Primary site)	-15.26±10.31	-9.288±6.539	0.0332*
Heat Detection Threshold (compared to BL skin temperature) (Forearm)	3.589±1.627	3.596 ± 1.654	0.9872
Heat Detection Threshold (compared to BL skin temperature) (Primary site)	4.233±1.547	4.078 ± 2.103	0.8000
Heat pain Threshold (compared to BL skin temperature) (Forearm)	8.307±3.234	8.126 ± 2.888	0.8534
Heat pain Threshold (compared to BL skin temperature) (Primary site)	8.522 ± 2.817	8.109 ± 2.805	0.6516
Pressure Pain Threshold (Trapezius)	296.0±121.2	222.4±79.85	0.0107*
Pressure Pain Threshold (Primary site)	608.2±304.2	372.3±173.3	0.0003***
Pressure Pain Tolerance (Trapezius)	466.8±253.0	357.4±177.4	0.0186*
Pressure Pain Tolerance (Primary site)	362.9±196.7	211.3±92.31	0.0009***
Conditioned Pain Modulation (Trapezius)	39.57±61.13	50.11±51.34	0.4759

*p< 0.05, **p< 0.01, ***p< 0.001

Supplementary Table 5. Patient with SCD Differed with HCs in Hematological Measures

Hematological Indexes	Parameter [Reference range]	TCM#1 (Equal) (n=12) (Mean±SD)	TCM#2 (Deficiency) (n=14) (Mean ± SD)	TCM#3 (Stagnation) (n=13) (Mean± SD)	Healthy (n=28) (Mean± SD)
	WBC (k/cumm) [3.6-10.6]	7.918±2.252	9.007±5.489**	9.738±3.469***	5.446±1.631
	RBC (million/cumm) [4.18-5.51]	3.105±0.7875****	2.639±0.6678****	3.379±0.7493****&	4.633±0.5746
Hemogram/Platelets	Hgb (GM/dL) [13.4-17.0]	10.13±2.169****	9.050±1.899****	10.23±1.494 ****	13.05 ± 1.584
/WBC Differential	Hct (%) [40.0-54.0]	28.65±6.320****	26.55±5.469****	30.12 ± 4.252 ****	39.33±4.367
	MCV (fL) [81-99]	93.82±12.28	103.1±17.26****	91.08±12.49&	85.25 ± 5.575
	MCH (pg) [27.0-34.0]	33.16±4.526*	35.16±6.541****	31.00±4.949	28.26 ± 2.286
	RDW (%) [11.5-14.5]	20.88±4.710****	19.89±4.293****	17.48±2.576**#	13.98 ± 0.8828
	Platelet (k/cumm) [150-450]	367.2±192.8*	331.0±170.1*	380.6±103.4**	241.7 ± 38.56
Reticulocytes	Reticulocyte Count (%) [0.5-2.5]	6.636±3.978****	5.846±3.678****	4.733±3.408 **	1.282±0.4982
	Absolute Retic Number (k/cumm) [21.0-115.0]	189.5±91.40****	147.7±91.51**	151.1±83.19**	60.20±27.44
	Hemoglobin A % [94.0-98.5]	16.80±5.657 ****	25.70±13.88****	13.34±11.15 ****	92.54±13.09
Hemoglobinopathy Studies	Hemoglobin F % [0.0-2.0]	9.288±8.363	15.08±10.68	8.970±7.746	N/A
	Hemoglobin S % [0.0-0.0]	65.64±16.64	67.05±11.63	57.91±18.04	N/A
	Hemoglobin A2 % [1.5-3.5]	2.933±0.9341	3.342±1.145	3.350±1.033	2.578±0.3029

*p< 0.05 compared with Healthy, **p< 0.01 compared with Healthy, ***p< 0.001 compared with Healthy, ***p< 0.0001 compared with Healthy, ****p< 0.0001 compared with Healthy, &p< 0.05 compared with Deficiency Group, #p< 0.05 compared with Equal Group.